Danske Bank A S Sells 101,689 Shares of Zoetis Inc. $ZTS

Key Points

• Danske Bank A/S trimmed its position in Zoetis by 25.6% in Q4, selling 101,689 shares and leaving it with 295,170 shares (about 0.07% of the company) valued at roughly $37.14 million.
• Zoetis topped Q4 estimates with EPS of $1.48 versus $1.40 and revenue of $2.39B versus $2.36B, and set FY2026 EPS guidance of $7.00–$7.10 (analysts’ consensus ~7.02).
• Dividend announced: Zoetis declared a $0.53 quarterly dividend (annualized $2.12, yield ~1.9%), ex-dividend date April 20 and payable June 2, with a payout ratio around 35.2%.

Danske Bank A S cut its stake in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 25.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 295,170 shares of the company's stock after selling 101,689 shares during the period. Danske Bank A S owned about 0.07% of Zoetis worth $37,138,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of ZTS. Global Wealth Strategies & Associates acquired a new stake in shares of Zoetis during the fourth quarter valued at about $25,000. KERR FINANCIAL PLANNING Corp acquired a new position in shares of Zoetis in the third quarter valued at approximately $31,000. Lodestone Wealth Management LLC acquired a new position in shares of Zoetis in the fourth quarter valued at approximately $30,000. Holos Integrated Wealth LLC bought a new position in Zoetis in the 4th quarter valued at approximately $32,000. Finally, Financial Consulate Inc. bought a new position in Zoetis in the 3rd quarter valued at approximately $39,000. 92.80% of the stock is currently owned by institutional investors.

Zoetis Stock Performance

Shares of ZTS stock opened at $114.22 on Friday. The stock has a market capitalization of $48.05 billion, a PE ratio of 18.97, a PEG ratio of 1.77 and a beta of 0.87. The business's 50 day simple moving average is $119.93 and its 200 day simple moving average is $124.79. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. Zoetis Inc. has a one year low of $112.97 and a one year high of $172.23.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The firm had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.36 billion. During the same quarter last year, the business earned $1.40 EPS. The company's revenue was up 3.0% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, research analysts forecast that Zoetis Inc. will post 7.02 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be issued a $0.53 dividend. The ex-dividend date is Monday, April 20th. This represents a $2.12 annualized dividend and a yield of 1.9%. Zoetis's payout ratio is presently 35.22%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on ZTS shares. Weiss Ratings lowered shares of Zoetis from a "hold (c-)" rating to a "sell (d+)" rating in a report on Friday, March 27th. William Blair reaffirmed an "outperform" rating on shares of Zoetis in a research note on Monday, March 2nd. BTIG Research reiterated a "buy" rating and set a $160.00 price target on shares of Zoetis in a report on Thursday, February 26th. Citigroup initiated coverage on shares of Zoetis in a research note on Wednesday, April 15th. They issued a "buy" rating and a $145.00 price objective on the stock. Finally, Leerink Partners restated a "market perform" rating on shares of Zoetis in a report on Tuesday, March 10th. Seven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Zoetis currently has an average rating of "Hold" and a consensus target price of $151.75.

About Zoetis

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.